Skip to main content
OpenTrials
Not Yet Recruiting

NCT Number: NCT07064954

Autologous Cold-stored Apheresis Platelets

The Auto-PLTS Study is a single-centre trial performed at Toronto General Hospital (TGH) that uses a randomized, patient preference design. The recent introduction of cold-stored platelets with a shelf-life of 14 days into clinical practice has made it possible to offer autologous apheresis platelet predonation to patients undergoing elective cardiac (and other high-blood-loss) surgeries while allowing sufficient time to recover platelet count before surgery. The Auto-PLTS Study is designed to assess whether replacing allogeneic platelets with autologous platelets will improve patient outcomes and benefit the healthcare system by reducing the burden on allogeneic platelet supply. The study is also designed to determine whether patients are willing to donate autologous platelets 7-10 days prior to surgery.

Not Yet Recruiting

Trial opening soon.

Get Notified

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2 / Phase 3

Primary location

Toronto General Hospital - University Health Network

Toronto, Ontario, M5G 2C4, Canada

Location contact

Justyna Bartoszko, MD MSc FRCPC

CONTACT

[email protected]

(416) 340-4800 ext. 3243

Justyna Bartoszko, MD MSc FRCPC

PRINCIPAL_INVESTIGATOR

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Adult (≥18 years old) patients who meet all following criteria:

  • Undergoing elective complex cardiac surgery consisting of at least one of the following:
  • Repair or replacement of more than one valve (i.e., multiple valves)
  • Repair or replacement of any segment of aortic arch
  • At least two of any combination of coronary artery bypass grafting (CABG), valve repair/replacement, or aorta (ascending/arch) repair/replacement
  • Complex adult congenital repair

Exclusion criteria

Patients who meet any of the following criteria are not eligible for the study:

  • Seven days or less from recruitment to surgery (as there will not be sufficient time from platelet donation to surgery for patients to recover their platelet count)
  • Patient factors that preclude platelet donation or increase risk of adverse events after donation, including any of the following:
  • Poor intravenous access
  • Low baseline platelet count (≤150,000 x106/L)
  • Low baseline hemoglobin (<100 g/L) (since approximately 50 mL of red blood cells are lost with each unit of apheresis platelet collection)
  • Inability to tolerate fluid shifts during donation (i.e., severe aortic stenosis with valve area <0.7 cm2, or left main coronary artery stenosis >80%, or left ventricular ejection fraction <30%)
  • Increased risk of bacterial contamination of collected units (i.e., active infection, on antibiotics, dental procedure <72 hours before donation)
  • Attending clinicians deem the patient ineligible for autologous predonation
  • Known positivity for active infectious blood-borne disease (HIV, HCV, HBV, HTLV, Syphilis)
  • Highly specialized procedures such as insertion or removal of ventricular assist devices or repair of thoracoabdominal aneurysm
  • Any history of congenital or acquired bleeding disorder (including any type of thrombocytopenia or platelet refractoriness due to anti-platelet and anti-HLA antibodies or requirement for specially matched platelets)
  • On any anticoagulant or antiplatelet medications, excluding ASA, that cannot be stopped at least 7 days before donation (72 hours for NSAIDs)
  • Refusal of allogeneic blood products due to religious or other reasons
  • Known or suspected pregnancy

Treatment and study plan

Autologous Cold-Stored Platelets

Biological

Two units of autologous platelets will be collected via an apheresis machine that draws blood from an intravenous (IV) line over 1-2 hours, isolates and leukoreduces the platelets by centrifugation and returns the remaining blood back to the patients. Collected autologous platelets will be stored at 1-6℃ without agitation until they are needed during or after surgery or 14 days have elapsed since their collection, after which they will be destroyed as per standard institutional procedures for expired blood products. For the first two platelet orders within 24 hours of cardiopulmonary bypass (CPB) termination, patients will receive their autologous cold-stored platelets. For the third and subsequent doses, patients in the intervention group will receive allogeneic room temperature-stored platelets (standard of care).

Allogeneic Room Temperature-Stored Platelets (Standard of Care)

Biological

Allogeneic platelets will be collected by Canadian Blood Services as per their standard operating procedures. Room temperature stored platelets will be stored at 20-24°C with constant agitation for up to 7 days as per current practices. For any platelet orders within 24 hours of cardiopulmonary bypass (CPB) termination, patients in the control group will receive allogeneic platelets as per usual care.

Primary outcomes

  1. Primary Efficacy Endpoint

    Time frame: up to 24 hours after termination of cardiopulmonary bypass (CPB)

    The incidence of allogeneic platelet transfusion during the treatment period

Study contacts

Contact information is provided by the study sponsor or research team.

Deep Grewal

CONTACT

[email protected]

416-340-4800 ext. 4221

Keyvan Karkouti, MD

CONTACT

[email protected]

416-340-4800 ext. 4221

Sponsors and collaborators

Lead sponsor

University Health Network, Toronto

Other

Registry information

Official study title

Auto-PLTS: The Effectiveness of Autologous, Cold-stored Platelets Collected 7-10 Days Before Cardiac Surgery for Avoidance of Allogeneic Transfusions: A Randomized Patient Preference Trial

Acronym: Auto-PLTS

Important dates

Study start
2025
Primary completion
2026
Study completion
2027
First posted
Jul 15, 2025
Registry last updated
Jul 22, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.